Arch Therapeutics Inc (QB) (ARTH) Quote

The float is over a million shares and only $1,373 worth of stock changed hands today.
Less than the price of one of Norchi's suits. Amazing.

Latest report,,,TOTAL REVENUE for 2023 was $45,800 or $3,800 per month. Let me repeat,,total REVENUE, $45,800 for the YEAR....how can this guy, Terry not end up is Prison,,,,how can anyone continue to loan him money...

That was the longest report I have ever read...talked 95% about years past...I never did see sales...???

Unfortunately, will go towards zero....Terry has made himself a great living for years, by milking this company

I wonder if December Medicare/Medicaid sales dropped.

If I’m wrong please correct me, if ARTH can’t hold $4 isn’t the up listing off the table?

It will continue to go up from here with anticipation of very good news.

Nice rebound today, still has legs!

He sees the writing on the wall...this company will be dark soon. I'm sad to say...Poorly run for years, but CEO has made out quite well...

VP of Sales, Dan Yrigoyen, resigned. He was expensive. The position did not seem to be a good fit.

I have no idea if this influenced the most recent drop in share price.

This POS is unfortunately showing its true colors..

SP getting killed today!

"Once it cross 11 then it will move fast."

It's more important to me how far it will move rather than how fast. Factoring in the most recent 1-for-200 reverse stock split the share price has what I think is an unfeasibly long row to hoe before I'm close to breaking even.

Once it cross 11 then it will move fast. We should be hearing soon on moving stock to upper stock exchange soon.

Going up. Huge bid. People want to get in before it goes on Nasdaq.

Wow. 12K+ volume in 5 minutes of opening. Selling done. Time to buy and take it to next high level.

It did hold 10 today. This tells me that it will be 20+ tomorrow.

That is my hope for sure, today was wild and hard to hold through that run.

They are going on Nasdaq in Jan 2024. This could be the reason they asked for advance. I believe float is locked and going to fly to the moon before goes into Nasdaq.

New to this site, started following ARTH based on Zacks ranking them as a Strong Buy and their top scoring stock for their combined ranking of value/growth/momentum. I am a bit concerned by the history of them and the recent $250K Shareholders Advance taken on 11/29.

wow. With only 100K it's going to 100%+. What will happen if this has 500K volume. I believe it will reach $100 with that volume. No shares available.

Another beauty day for ARTH!

Deleted

Searching and seaching for one simple answer: WHAT THE HELL IS GOING ONE?????

wow, second round has started. It will cross $10 this time.

I think the Lazarus moment is because ARTH was given an extension until early January 2024 to up list and this may be viewed by some as a positive that will take a future reverse split off the table.

I'm not excited by the current stock price as I think it has some characteristics of a pump 'n dump.

Have no idea what is going on. Appears to have risen from the Dead with no news and relatively small volume.

Congrats

Yep

No posts on this board for months, the pps explodes in the last weeks..... and.....Silence.

Anyone else notice the share price has been .666 for some time now? Weird.

You are Correct..imho

This is Norchi's retirement plan.
He has screwed this up so much he knows he can never get another job in the industry so he will milk this as long as he can.

I am sad to say I've been in the stock for 8 years at least he doesn't know his butt from first base talking about Norchi... he knows how to keep the company afloat so he can get that huge paycheck every month. That's all this is about now

I'm not qualified to judge the legality of Norchi's actions but I do feel I am qualified to assess this most recent action as blatantly underhanded.

"What Norchi has done and continues to do HAS to be illegal,don't u think"

What Norchi has done and continues to do HAS to be illegal,,don't u think

Arch Therapeutics has been pretty much over for me for awhile now. Recent actions have eliminated any remaining doubts I may have had.

ARTH dropped 31% on Thursday 9/7/23 after a series of SEC filings. On September 1 they filed a Form 14C informing us that certain actions were taken by the written consent of the holders of a majority of the outstanding voting stock in lieu of a meeting. They increased the number of authorized shares of stock from 12,000,000 to 350,000,000 shares. Then said the Board can approve another reverse split between 1-for-1.5 and 1-for-20.

On September 6 they filed an 8-K to amend the convertible notes to extend the date of the required up list to NASDAQ from August 31 to September 30. That means another reverse split is imminent because they need a stock price over $4 to up list.

In the future, anytime I get a whiff of a stock contemplating a reverse split I am selling what I own, walking away, and never looking back.

POS keeps going down. There is no what that a crime has been committed by Norchi...personal cash reagistar

13G filed today..anyone know who this is for

Currently extending maturity of financing until a new exchange listing (July). $4M market cap for the last decade. Commercial since 2019

All things considered, the stock price is actually holding up well.
No money coming in, no prospect of any money coming in, and yet it has been fairly stable.
I was sure it would be down to a buck by now.

This has always been just a money machine for CEO Terry N...isn't that against the law??

Inventory - 88% of assets; 3-mo revenue of $16K, increase of SG&A of $43K

10Q will be filed late.

“ PART III — NARRATIVE

State below in reasonable detail the reasons why Forms 10-K, 20-F, 11-K, 10-Q, 10-D, N-SAR, N-CSR, or the transition report or portion thereof, could not be filed within the prescribed time period.

Arch Therapeutics, Inc. (the “Company”) is unable to file its Quarterly Report on Form 10-Q for the period ended March 31, 2023 by the prescribed due date without unreasonable effort or expense because of the circumstances described below.

“The Company's Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2023, cannot be filed within the prescribed time period because the Company requires additional time for compilation and review to insure adequate disclosure of certain information required to be included in the Quarterly Report on Form 10-Q, including the XBRL (eXtensible Business Reporting Language) Interactive Data Files for the financial statements and notes included in the Quarterly Report. The Company's Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2023 will be filed on or before the 5th calendar day following the prescribed due date.”

Waiting for revenue numbers instead of conference presentations. Expect to have major inventory write-off in the not so distant future. Exec comp will probably exceed R&D and sales expenses combined.

What a piece of Shat...Great job Terry

I barely hold any shares and it’s almost funny seeing the amount of sales and the volume of trading in the stock…. However, seeing what Norchi did to shareholders isn’t really that funny. What an a hole.

3 years post FDA clearance & TN tries a sales force.

Market Cap $4.1M & falling.

60 minutes will eventually do a Con story about Terry, how he has milked this cow for Years with NO REGARDS for shareholders...

Forget share price; market cap declined to under $6M since reverse split. Share price in current range may help raise more funds. Price seemingly supported for the moment by careful trading by key holders & broker dealer.